Skip to content

EFFECT OF MAHA MANJISHTATHY KASHAYAM(INTERNAL)AND AADUTHENDAPALAI VEMBU ENNAI (EXTERNAL)ON KALANJAGAPADAI(PSORIASIS)IN CHILDREN

CLINICAL EVALUATION OF MAHA MANJISHTATHY KASHAYAM(INTERNAL)AND AADUTHENDAPALAI VEMBU ENNAI (EXTERNAL)FOR THE MANAGEMENT OF KALANJAGAPADAI(PSORIASIS)IN CHILDREN

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/043877
Enrollment
30
Registered
2022-07-08
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere

Interventions

Intervention1: Maha Manjishtathy Kashayam(Internal) Aaduthendapalai Vembu Ennai(External): Dosage for Maha Manjishtathy Kashayam:10-15ml twice a day after food. Aaduthendapalai Vembu Ennai-External us

Sponsors

National Institute of Siddha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Erythema thickness scaling with/without itching cracks followed by itching, dryness of skin. 2.Patient informant/Parent and Patient are willing to sign the informed consent form and assent form stating that he/she will consciously stick to the treatment during 60 days but can opt out of the trial of his/her own conscious discretion 3. Willing to cooperate for taking photographs whenever required with his/her consent.

Exclusion criteria

Exclusion criteria: 1 Eczema 2 Psoriasis with evidence of any other skin diseases 3 Fungal infections 4 Systemic involvement 5 Lesions with secondary infections 6 Epilepsy 7Any other serious illness

Design outcomes

Primary

MeasureTime frame
Efficacy of trial drug measured using Psoriasis area Scoring Index(PASI)Timepoint: 60days

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactDr G Subashini

National Institute of Siddha

drarulmozhi@yahoo.co.in9500151930

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026